| 产品编号 | bsm-56202R |
| 英文名称 | VEGFA Recombinant Rabbit mAb |
| 中文名称 | 血管内皮生长因子重组兔单抗 |
| 别 名 | Vascuoar endothelial growth factor A; VEGF A; vascular endothelial growth factor A isoform 2 precursor; MGC70609; MVCD1; VEGF; VPF; VEGFA_HUMAN; VEGF-A; Vascular permeability factor(VPF); |
| 抗体来源 | Rabbit |
| 克隆类型 | Recombinant |
| 克 隆 号 | 4G7 |
| 交叉反应 | Human,Mouse,Rat |
| 产品应用 | IHC-P=1:50-200,IHC-F=1:50-200,IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 24 kDa |
| 检测分子量 | |
| 细胞定位 | 分泌型蛋白 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human VEGF |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | PBS (pH7.2) with 40% Glycerol, 0.05% BSA and 0.02% Proclin300. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF), is a signal protein produced by cells that stimulates the formation of blood vessels. To be specific, VEGF is a sub-family of growth factors, the platelet-derived growth factor family of cystine-knot growth factors. They are important signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). Function: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Subunit: Homodimer; disulfide-linked. Also found as heterodimer with PGF (By similarity). Subcellular Location: Secreted. Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. Tissue Specificity: soform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. DISEASE: Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Similarity: Belongs to the PDGF/VEGF growth factor family. SWISS: P15692 Gene ID: 7422 Database links: Entrez Gene: 7422 Human Entrez Gene: 22339 Mouse Omim: 192240 Human SwissProt: P15692 Human SwissProt: Q00731 Mouse Unigene: 73793 Human Unigene: 282184 Mouse Unigene: 1923 Rat 生长因子和激素(Growth Factor and Hormones) 血管内皮细胞生长因子(VEGF)是一种特异作用于血管内皮细胞的多功能细胞因子,它能引起血管通透性增加,引起细胞外基质成分改变,诱导血管形成.在炎症、创伤愈合、心脏缺血、动脉粥样硬化、糖尿病性视网膜病变及肿瘤形成等与血管生成和病变有关的诸多病理过程中起重要作用. VEGF与血管生成有关，从而也与肿瘤生长也有很大关系,近年来受到很多关注. |
| 产品图片 |
Paraformaldehyde-fixed, paraffin embedded Human Placenta; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFA Monoclonal Antibody, Unconjugated(bsm-56202R) at 1:200overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Rat Kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFA Monoclonal Antibody, Unconjugated(bsm-56202R) at 1:200overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Mouse Kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFA Monoclonal Antibody, Unconjugated(bsm-56202R) at 1:200overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Lung Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFA Monoclonal Antibody, Unconjugated(bsm-56202R) at 1:200overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Liver Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFA Monoclonal Antibody, Unconjugated(bsm-56202R) at 1:200overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Liver ; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFA Monoclonal Antibody, Unconjugated(bsm-56202R) at 1:200overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFA Monoclonal Antibody, Unconjugated(bsm-56202R) at 1:200overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
